Kite Pharma To Highlight Cancer Immunotherapy T Cell Manufacturing Process At 2014 ASCO Annual Meeting - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Kite Pharma To Highlight Cancer Immunotherapy T Cell Manufacturing Process At 2014 ASCO Annual Meeting


Kite Pharma To Highlight Cancer Immunotherapy T Cell Manufacturing Process At 2014 ASCO Annual Meeting

PR Newswire

SANTA MONICA, Calif., May 30, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the Company will provide details on key features of the rapid, 6-day manufacturing process that is expected to underlie its most advanced personalized cancer immunotherapy program.  The technology is expected to underpin a Kite clinical trial in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL), a highly refractory and aggressive blood cancer, which Kite expects to commence in early 2015.  Elements of Kite's manufacturing process will be featured in a poster presentation during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, May 30 to June 3, 2014.

ASCO 2014 Poster Presentation
Title:  Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR.

Authors:  Marc Better 1, Omar Pugach 1, Lily Lu 2, Robert Somerville 2, Sadik Kassim 2, James Kochenderfer 2, Steven A. Rosenberg 2, Margaret A. Marshall 1, Adrian Bot1, Keith B. Nolop 1, Margo Roberts 1, Steven Feldman 2.  Key:  1  Kite Pharma, 2  National Cancer Institute

Abstract:  #3079

Poster:  #146

General Poster Session:  Developmental Therapeutics - Immunotherapy

Date and Location:  Sunday, June 1, 2014, 8:00am11:45am Central Time; S Hall A2

About Kite Pharma
Kite Pharma, Inc., is a privately held clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors.  In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications.  Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments.  Kite is based in Santa Monica, CA.

Kite Contact:
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
310-824-9999

For Media: Justin Jackson
For Investor Inquiries: Kimberly Minarovich
Burns McClellan
(212) 213-0006
jjackson@burnsmc.com
kminarovich@burnsmc.com

SOURCE Kite Pharma, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here